Skip Navigation
  • We are Hiring
  • Contact Us
  • Search Toggle
Kezar Life Sciences logo
  • About
    • About
      Kezar
    • Our Company
    • Our Team
    • Board of Directors
    • Contact Us
  • Pipeline
    • Our
      Pipeline
    • Our Pipeline
    • Zetomipzomib (KZR-616)
    • KZR-261
  • Science
    • Our
      Science
    • Selective Immuno–proteasome Inhibition
    • Protein Secretion Inhibition
    • Scientific Publications
  • Patients
    • Our
      Patients
    • Disease Education
    • Patient Advocacy
    • Clinical Trials
  • Investors & Media
    • Investors
      Media
    • Investors & Media Home
    • News & Events
      • Press Releases
      • Events &
        Presentations
    • Stock Information
      • Stock Quote Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Financials & Filings
      • SEC Filings
    • Corporate
      Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
    • Investor Resources
      • Investor FAQs
      • Investor Contact
      • Email Alerts
  • Careers
    • Kezar
      Careers
    • Join Our Team
    • Job Opportunities
Kezar Pipeline header

Publications

11.11.19

Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of Kzr-616, a Selective Inhibitor of the Immunoproteasome

.American College of Rheumatology (ACR 2019).
Kezar Life Sciences logo
4000 Shoreline Court
Suite 300
South San Francisco, CA 94080
contact@kezarbio.com
(650) 822-5600
Visit us on LinkedIn
Visit us on Twitter
Visit us on Youtube
Visit us on Facebook

©2022 Kezar Life Sciences Inc.. All Rights Reserved.

  • Privacy Policy
  • Disclaimer
  • Site Map